Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Prevention of aGVHD After Allogeneic HSCT
NCT03840512Phase 2Unknown
- Sponsor
- Claritas Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of cannabidiol in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Claritas Pharmaceuticals. Primary endpoints: Adverse Events (AEs) and serious adverse events (SAEs) Reporting, Cumulative incidence of aGVHD at day 100 post-transplant and 8 more. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03840512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840512.